# US 2006/0135454 A1 · Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0135454 A1
- Document ID: US20060135454A1
- Status: Published application
- Kind: A1
- Application number: 10/694,207
- Filed: 2003-10-27
- Published: 2006-06-22
- Earliest claimed: 2000-09-26
- Assignees: Idera Pharmaceuticals, Inc.
- Inventors: Ekambar Kandimalla; Qiuyan Zhao; Dong Yu; Sudhir Agrawal
- Web page: https://patentgrep.com/patent/US20060135454A1

## CPC

- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- C12N 2310/18: acting by a non-sequence specific mechanism
- C12N 2310/3125: Methylphosphonates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/318: where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N 2310/32: of the sugar
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/33: of the base
- C12N 2310/334: Modified C
- C12N 2310/336: Modified G
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A method for generating an immune response in a patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the oligonucleotide analog immunostimulatory compound is administered in combination with an antibiotic, antigen, allergen, vaccine, antibody, cytotoxic agent, antisense oligonucleotide, gene therapy vector, DNA vaccine, adjuvant, or combination thereof.

### Claim 28 (depends on 26)

The method according to claim 26, wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.

### Claim 29 (depends on 28)

The method according to claim 28, wherein such conjugation is to the 3′-end of the oligonucleotide compound.

### Claim 30

A method for therapeutically treating a patient having disease caused by a pathogen, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the pathogen is a virus.

### Claim 32 (depends on 30)

The method according to claim 30, wherein the pathogen is a parasite.

### Claim 33 (depends on 30)

The method according to claim 30, wherein the pathogen is a bacterium.

### Claim 34

A method for treating a cancer patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the immunostimulatory oligonucleotide compound is administered in combination with a chemotherapeutic compound.

### Claim 36

A method for treating an autoimmune disorder, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the autoimmune disorder is autoimmune asthma.

### Claim 38

A method for treating airway inflammation or allergy, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside.

### Claim 39

A method for generating an immune response in a patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.

### Claim 40 (depends on 39)

The method according to claim 39, wherein such conjugation is to the 3′-end of the oligonucleotide compound.

### Claim 41 (depends on 39)

The method according to claim 39, wherein the oligonucleotide analog immunostimulatory compound is administered in combination with an antibiotic, allergen, antibody, cytotoxic agent, antisense oligonucleotide, gene therapy vector, DNA vaccine, adjuvant, or combination thereof.

### Claim 42

A method for therapeutically treating a patient having disease caused by a pathogen, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.

### Claim 43 (depends on 42)

The method according to claim 42, wherein such conjugation is to the 3′-end of the oligonucleotide compound.

### Claim 44 (depends on 42)

The method according to claim 42, wherein the pathogen is a virus.

### Claim 45 (depends on 42)

The method according to claim 42, wherein the pathogen is a parasite.

### Claim 46 (depends on 42)

The method according to claim 42, wherein the pathogen is a bacterium.

### Claim 47

A method for treating a cancer patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.

### Claim 48 (depends on 47)

The method according to claim 47, wherein such conjugation is to the 3′-end of the oligonucleotide compound.

### Claim 49 (depends on 47)

The method according to claim 47, wherein the immunostimulatory oligonucleotide compound is administered in combination with a chemotherapeutic compound.

### Claim 50

A method for treating an autoimmune disorder, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.

### Claim 51 (depends on 51)

The method according to claim 51, wherein such conjugation is to the 3′-end of the oligonucleotide compound.

### Claim 52 (depends on 50)

The method according to claim 50, wherein the autoimmune disorder is autoimmune asthma.

### Claim 53

A method for treating airway inflammation or allergy, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula 5′-pyrimidine-purine-3′, wherein pyrimidine is a natural or non-natural pyrimidine nucleoside and purine is a natural or non-natural purine nucleoside, and wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.

### Claim 54 (depends on 53)

The method according to claim 53, wherein such conjugation is to the 3′-end of the oligonucleotide compound.
